文献速递血栓与止血

一种通过结合FcγIIa受体激活血小板的αIIbβ3配体模拟型鼠单克隆抗体

An αIIbβ3 ligand-mimetic murine monoclonal antibody that produces platelet activation by engaging the FcγIIa receptor.
PubMed 文献 · Blood Adv · 2025-01-01

研究用人类血小板免疫小鼠制备结合αIIbβ3并抑制血块回缩的鼠单克隆抗体R6H8。R6H8在20 μg/mL完全抑制血块回缩,在5 μg/mL却经FcγRIIa激活血小板,20 μg/mL抑制SFLLRN诱导的聚集。冷冻电镜显示其通过重链RYD序列结合αIIbβ3并引起β3结构重排。

要点

  • R6H8在20 μg/mL完全抑制血块回缩,在5 μg/mL经FcγRIIa激活血小板。
  • R6H8的Fab段不诱导血小板聚集,完整抗体聚集可被FcγRIIa阻断抗体IV.3抑制。
  • R6H8通过重链CDR3的RYD序列结合αIIbβ3配体结合口袋并引起β3杂合域摆动。

核心结论

  • R6H8是一种αIIbβ3配体模拟型单克隆抗体,低浓度时经FcγRIIa激活血小板,高浓度时强力抑制血小板聚集和血块回缩。
  • R6H8可模拟多种病理抗体,包括αIIbβ3抑制剂治疗后出现的血小板激活抗体、肝素诱导的血小板减少症和疫苗诱导的免疫性血栓性血小板减少症中的血小板激活抗体。
  • 因此,R6H8可能是更好地理解这些疾病并识别潜在疗法的有价值试剂。

研究设计与样本

  • 研究用人类血小板免疫小鼠,检测杂交瘤上清结合αIIbβ3和抑制血块回缩的能力,获得鼠单克隆抗体R6H8。
  • 用单克隆抗体IV.3阻断FcγRIIa、R6H8的Fab片段及冷冻电镜分析R6H8 Fab-αIIbβ3复合物研究其作用机制。

主要发现

  • 免疫球蛋白G1(IgG1)单克隆抗体R6H8在20 μg/mL完全抑制血块回缩。
  • 在5 μg/mL,R6H8启动血小板聚集并诱导P-选择素表达、纤维蛋白原结合和PAC-1结合。
  • 在20 μg/mL,R6H8完全抑制凝血酶PAR-1受体激活肽SFLLRN(T6;25 μg/mL)诱导的聚集及T6诱导的血小板纤维蛋白原和PAC-1结合。
  • R6H8诱导的血小板聚集可被阻断FcγRIIa的单克隆抗体IV.3抑制,而R6H8的Fab片段不诱导血小板聚集。
  • 冷冻电镜显示R6H8通过重链互补决定区3的Arg-Tyr-Asp(RYD)序列结合αIIbβ3的RGD结合口袋,与β3 Asp126相互作用引起Asp126重定向并丢失邻近金属离子依赖性黏附位点的Ca2+,并启动β3杂合域摆动。

关键数值与推荐

  • R6H8在20 μg/mL完全抑制血块回缩。
  • R6H8在5 μg/mL启动血小板聚集并诱导P-选择素表达、纤维蛋白原结合和PAC-1结合。
  • R6H8在20 μg/mL完全抑制SFLLRN(T6;25 μg/mL)诱导的血小板聚集及纤维蛋白原和PAC-1结合。
  • R6H8的Fab-αIIbβ3复合物冷冻电镜显示其通过重链CDR3的RYD序列结合αIIbβ3 RGD结合口袋。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To produce a murine monoclonal antibody (mAb) that binds to glycoprotein IIb/IIIa (αIIbβ3) and inhibits clot retraction (CR), we immunized mice with human platelets and tested hybridoma supernatants for their ability to bind to αIIbβ3 and inhibit CR. The immunoglobulin G1 (IgG1) mAb R6H8 completely inhibited CR at 20 μg/mL. Paradoxically, at 5 μg/mL, R6H8 initiated platelet aggregation and induced P-selectin expression, fibrinogen binding, and PAC-1 binding. At 20 μg/mL, however, R6H8 completely inhibited aggregation induced by thrombin PAR-1 receptor activating peptide SFLLRN (T6; 25 μg/mL) and T6-induced fibrinogen and PAC-1 binding to platelets. Platelet aggregation induced by R6H8 was inhibited by mAb IV.3, which blocks the FcγIIa receptor (FcγRIIa), and the Fab fragment of R6H8 did not induce platelet aggregation, suggesting that R6H8 binds to both αIIbβ3 and FcγRIIa. Cryogenic electron microscopy analysis of the R6H8 Fab-αIIbβ3 complex revealed that R6H8 (1) binds to the αIIbβ3 RGD binding pocket via an Arg-Tyr-Asp (RYD) sequence in its heavy chain complementarity-determining region 3; (2) interacts with β3 Asp126, producing a reorientation of Asp126 and loss of the adjacent to metal ion-dependent adhesion site Ca2+; and (3) initiates swing-out of the β3 hybrid domain. We conclude that R6H8 is an αIIbβ3 ligand-mimetic mAb that activates platelets via FcγRIIa at low concentrations and potently inhibits platelet aggregation and CR at high concentrations. R6H8 simulates the actions of a number of pathological antibodies, including platelet-activating antibodies developed after therapy with αIIbβ3 inhibitors and platelet-activating antibodies in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. As such, it may be a valuable reagent for better understanding these disorders and identifying potential therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wang J, Buitrago L, Wang L, et al. An αIIbβ3 ligand-mimetic murine monoclonal antibody that produces platelet activation by engaging the FcγIIa receptor. Blood Adv. 2025. PMID: 40101235. doi:10.1182/bloodadvances.2024015368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。